Bristol Myers Squibb

Milestones as listed on bms.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Leadership as listed on bms.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Products and services as listed on bms.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Sites as listed on bms.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

What public registers list for Bristol Myers Squibb (group figures): clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 7 Oct 2026.

Clinical trials 203 in our ClinicalTrials.gov registers · 16 in the EU register

Showing 10 of 203, trials with Irish sites first. The full lists are on the sponsor pages below.

All trials by sponsor name 2 registry names

Drugs in these trials 124 compounds

EU trials register (CTIS) 16 authorised or ongoing · 2 in Ireland

• ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC)2026-527163-15-00 · Phase I/II · Authorised · site in Ireland
• IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis2025-522373-10-00 · Phase III · Authorised · site in Ireland
• A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants with Refractory Rheumatoid Arthritis2025-520666-22-00 · Phase I/II · Ongoing
• A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants2025-524564-38-00 · Phase I · Authorised
• ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)2025-523602-33-00 · Phase I/II · Ongoing
• CN012-0025: A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-3)2024-519994-20-00 · Phase III · Ongoing
• Phase 1/1b Study of BMS-986463 in Advanced Malignant Tumors2025-523067-38-01 · Phase I · Authorised
• A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc)2025-524337-11-00 · Phase III · Authorised

Medicine shortages 2 in the FDA list

• Azacitidine InjectionUS (FDA) · in shortage · updated 3 Oct 2026
• Atazanavir Sulfate; Cobicistat TabletUS (FDA) · resolved · updated 3 Nov 2025

A company is listed here when it is named on the shortage record; a shortage can have several manufacturers. See the US and German shortage trackers.

NICE technology appraisals 61 of its medicines · 60 current

• Lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (terminated evaluation)NICE TA1186 · Terminated (no company submission) · 20 Aug 2026
• Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatmentNICE TA1159 · Optimised · 3 Jun 2026
• Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)NICE TA1141 · Terminated (no company submission) · 17 Mar 2026
• Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancerNICE TA1127 · Optimised · 4 Feb 2026
• Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal)NICE TA1083 · Terminated (no company submission) · 23 Jul 2025
• Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal)NICE TA1084 · Terminated (no company submission) · 23 Jul 2025
• Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)NICE TA1076 · Terminated (no company submission) · 2 Jul 2025
• Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyNICE TA1065 · Recommended · 28 May 2025

Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Group (Bristol Myers Squibb): founded 1989, headquarters New York City, website bms.com. Wikidata Q266423 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.

How this is matched: register records are linked to this page by the organisation name they carry, here Bristol-Myers Squibb; Celgene; Bristol-Myers Squibb Services Unlimited Company; Celgene Corp.; Bristol-Myers Squibb Pharmaceuticals uc; Bristol-Myers Squibb Pharma EEIG and 7 more. Spot a wrong match? Tell us.

Group figures for Bristol-Myers Squibb Company, the parent company. From the annual reports Bristol-Myers Squibb Company files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.

Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.

Companies registered in Ireland 9 active in the CRO register

From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Bristol-Myers Squibb Company as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.